Skip NavigationSkip to Content

Evaluation of TypeSeq, a Novel High-Throughput, Low-Cost, Next-Generation Sequencing-Based Assay for Detection of 51 Human Papillomavirus Genotypes

  1. Author:
    Wagner,Sarah
    Roberson, David
    Boland,Joseph
    Kreimer, Aimée R
    Yeager,Meredith
    Cullen,Michael
    Mirabello, Lisa
    Dunn, S Terence
    Walker, Joan
    Zuna, Rosemary
    Porras, Carolina
    Cortes, Bernal
    Sampson, Joshua
    Herrero, Rolando
    Rodriguez, Ana Cecilia
    Quint, Wim
    Van Doorn, Leen-Jan
    Hildesheim, Allan
    Schiffman, Mark
    Wentzensen, Nicolas
  2. Author Address

    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland., Cancer Genomics Research Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Maryland., University of Oklahoma Health Sciences Center, Oklahoma City., Agencia Costarricense de Investigaciones Biomedicas, San Jos 233;, Costa Rica., International Agency for Research on Cancer, World Health Organization, Lyon, France., DDL Diagnostic Laboratory, Rijswijk, The Netherlands.,
    1. Year: 2019
    2. Date: NOV 15
    3. Epub Date: 2019 06 26
  1. Journal: The Journal of infectious diseases
    1. 220
    2. 10
    3. Pages: 1609-1619
  2. Type of Article: Article
  3. ISSN: 0022-1899
  1. Abstract:

    Background. Human papillomaviruses (HPV) cause over 500 000 cervical cancers each year, most of which occur in low-resource settings. Human papillomavirus genotyping is important to study natural history and vaccine efficacy. We evaluated TypeSeq, a novel, next-generation, sequencing-based assay that detects 51 HPV genotypes, in 2 large international epidemiologic studies. Methods. TypeSeq was evaluated in 2804 cervical specimens from the Study to Understand Cervical Cancer Endpoints and Early Determinants (SUCCEED) and in 2357 specimens from the Costa Rica Vaccine Trial (CVT). Positive agreement and risks of precancer for individual genotypes were calculated for TypeSeq in comparison to Linear Array (SUCCEED). In CVT, positive agreement and vaccine efficacy were calculated for TypeSeq and SPF10-LiPA. Results. We observed high overall and positive agreement for most genotypes between TypeSeq and Linear Array in SUCCEED and SPF10-LiPA in CVT. There was no significant difference in risk of precancer between TypeSeq and Linear Array in SUCCEED or in estimates of vaccine efficacy between TypeSeq and SPF10-LiPA in CVT. Conclusions. The agreement of TypeSeq with Linear Array and SPF10-LiPA, 2 well established standards for HPV genotyping, demonstrates its high accuracy. TypeSeq provides high-throughput, affordable HPV genotyping for world-wide studies of cervical precancer risk and of HPV vaccine efficacy.

    See More

External Sources

  1. DOI: 10.1093/infdis/jiz324
  2. PMID: 31536132
  3. WOS: 000491241900009
  4. PII : 5523741

Library Notes

  1. Fiscal Year: FY2018-2019
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel